|
Association of CD44/CD24 phenotypes with breast cancer subgroups. |
|||||||
| Phenotype |
All tumors (n = 232) |
SR+HER2- (n = 150) |
SR+HER2+ (n = 14) |
SR-HER2+ (n = 24) |
SR-HER2- |
P valuea |
|
|
|
|||||||
| Basal-like (n = 30) |
Nonbasal (n = 14) |
||||||
|
|
|||||||
| CD44 |
0.001 |
||||||
| Positive (> 0%) |
75 (32) |
47 (31) |
2 (14) |
4 (17) |
19 (63) |
3 (21) |
|
| Negative |
157 (68) |
103 (69) |
12 (86) |
20 (83) |
11 (37) |
11 (78) |
|
| CD24 |
0.035 |
||||||
| Positive (> 0%) |
108 (47) |
65 (43) |
8 (57) |
18 (75) |
12 (40) |
5 (36) |
|
| Negative |
124 (53) |
85 (57) |
6 (43) |
6 (25) |
18 (60) |
9 (64) |
|
| CD44+/CD24- |
< 0.001 |
||||||
| Positive (> 0%) |
73 (31) |
47 (31) |
2 (14) |
2 (8) |
19 (63) |
3 (21) |
|
| Negative |
159 (69) |
103 (69) |
12 (86) |
22 (92) |
11 (37) |
11 (79) |
|
| CD44-/CD24+ |
0.027 |
||||||
| Positive (> 0%) |
106 (46) |
63 (42) |
8 (57) |
18 (75) |
12 (40) |
5 (36) |
|
| Negative |
126 (54) |
87 (58) |
6 (43) |
6 (25) |
18 (60) |
9 (64) |
|
| CD44+/CD24+ |
0.61 |
||||||
| Positive (> 0%) |
14 (6) |
9 (6) |
0 (0) |
3 (12) |
2 (7) |
0 (0) |
|
| Negative |
218 (94) |
141 (94) |
14 (100) |
21 (88) |
28 (93) |
14 (100) |
|
| CD44-/CD24- |
0.28 |
||||||
| 100% |
78 (28) |
57 (31) |
4 (24) |
5 (18) |
6 (18) |
6 (40) |
|
| < 100% |
197 (72) |
125 (69) |
13 (76) |
23 (82) |
27 (82) |
9 (60) |
|
|
Data presented as n (%). SR, steroid receptor. aP values were calculated using Fisher's exact test. | |||||||
Honeth et al. Breast Cancer Research 2008 10:R53 doi:10.1186/bcr2108 |
|||||||